Novo CEO pressed by Senate to cut costs of obesity, diabetes medicines CEO Lars Fruergaard Jørgensen explained to lawmakers the company would think about new talks with insurers regarding the listing charges of Wegovy and copyright when they pledge to keep the medicines on their formularies. This plan aligns with https://kethek.com/